martes, 6 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 18, 2026

Bank of America revamps Tesla forecast before earnings

View original at finance.yahoo.com
Bank of America revamps Tesla forecast before earnings Tesla (TSLA) CEO Elon Musk, whom JPMorgan CEO Jamie Dimon once called "our Einstein", has had plenty on his plate lately…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Bank of America reiterated its Buy rating and $460 price target on Tesla, implying nearly 17.6% upside from Tesla's July 17 close of $391.06

    60% confidence

  • BofA's Tesla EPS estimates jumped to $2.13, $2.71, and $3.39 for 2026, 2027, and 2028 respectively, representing increases of nearly 7%, 4%, and 4%

    60% confidence

  • BofA lifted its 2026 Tesla revenue estimate to $107.8 billion from $103.4 billion

    60% confidence

  • BofA's quarterly model points to acceleration in Tesla's adjusted EPS, reaching $0.51 in Q2, $0.54 in Q3, and $0.68 in Q4 2026

    60% confidence

  • BofA raised its 2027 Tesla revenue estimate to $126.2 billion from $120.4 billion

    60% confidence

  • BofA raised its 2028 Tesla revenue estimate to $144 billion from $137.2 billion

    60% confidence

  • Jamie Dimon once called Elon Musk "our Einstein"

    60% confidence

  • Robotaxi is the primary catalyst spearheading Tesla's bull case, with Tesla entering the early monetization phase for robotaxis, FSD, Optimus, and energy storage

    60% confidence

Data points we hold from this source

SpaceX · stock price123.99 USD
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com